This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.0 (cystinosis, cystine storage disease (N29.8*)) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Cystine storage disease, CTNS deficiency, Nephropathic cystinosis, Infantile cystinosis, Lysosomal cystine transport disease, Cystinosin deficiency |
| C. Adult onset | Likelihood of first presentation in adulthood low — nephropathic (infantile) cystinosis presents with Fanconi syndrome at 6–12 months of age and is diagnosed in childhood, so first diagnosis in adulthood is rare; however, in juvenile/adult (intermediate) cystinosis, renal failure is sometimes first diagnosed at 15–25 years of age; the ocular (adult) form may be first found in adulthood because of corneal cystine crystals and photosensitivity. |
| 1. History | First reported by Abderhalden in 1903 (tissue deposition of cystine crystals) → named cystinosis by Lignac in 1924 → intracellular cystine excess confirmed in 1957 → lysosomal cystine accumulation demonstrated in 1969 → CTNS gene discovered in 1995 → first cysteamine treatment in 1976 → approval of delayed-release cysteamine in 2013. |
| 2. Causes | Mutations in the CTNS gene (encoding cystinosin) on the short arm of chromosome 17 (17p13.2). Deficiency of the lysosomal cystine transporter (cystinosin) → accumulation of cystine crystals in lysosomes → cell death and organ damage. 57 kb deletion in about 60% of Western European patients. |
| 3. Genetics | Autosomal recessive. CTNS gene (17p13.2), 12 exons. Most common variant: 57 kb deletion (including exons 1–10, ~60% of Western European patients). Point mutations frequent in Korea and Asia. Homozygous/compound heterozygous. Phenotypes: infantile (severe), juvenile/intermediate, adult ocular. |
| 4. General epidemiology | About 1 in 100,000–200,000 births worldwide. Nephropathic (infantile) form about 95% of the total. An estimated 2,000 living patients worldwide. Diagnosed cases exist in Korea, but the exact prevalence is unknown. Not related to race or region. |
| 5. Pathophysiology | Cystinosin deficiency → accumulation of cystine crystals in lysosomes → apoptosis and mitochondrial dysfunction → ATP deficiency → loss of function of Na⁺-dependent transporters in the proximal tubule → Fanconi syndrome. Cystine crystals deposit in multiple systems, including the cornea, muscle, thyroid, pancreas and nervous system. |
| 6. Symptoms | Infantile (from 6–12 months of age): polyuria and polydipsia, growth failure, rickets, metabolic acidosis, corneal photosensitivity. Childhood: declining renal function → ESRD (at 10–12 years without treatment). Juvenile form: renal failure at 10–25 years. Adult form: corneal cystine crystals and photosensitivity only. Multisystem: myopathy, dysphagia, pulmonary insufficiency, diabetes, neurocognitive impairment. |
| 7. Signs | Corneal cystine crystals on slit lamp (after 6 months). Growth failure and rickets (genu valgum, rachitic rosary). Urine: glucosuria, aminoaciduria, low-molecular-weight proteinuria. Serum: hypophosphatemia, hypokalemia, metabolic acidosis. Elevated serum creatinine (CKD progression). Muscle weakness (with progression). |
| 8. Screening | Newborn screening: not included in national NBS (Korea). Infants with a family history: early urinalysis (glucosuria, aminoaciduria) + serum electrolyte measurement. Confirmatory test: leukocyte free cystine measurement (normal <0.2 nmol/mg protein). Ophthalmology: slit lamp examination (corneal crystals). Genetic testing: CTNS analysis. |
| 9. Diagnosis | Quantification of free cystine in leukocytes or polymorphonuclear leukocytes (confirmation: ≥0.5 nmol/mg protein). CTNS gene analysis (NGS, or MLPA to detect the 57 kb deletion). Confirmation of cystine crystals on corneal slit lamp examination. Urine amino acid quantification, calculation of phosphate TRP, β2-microglobulin. Kidney biopsy (electron microscopic confirmation of lysosomal cystine crystals). |
| 10. Treatment | Core treatment: oral cysteamine (50–90 mg/kg/day in 4 divided doses, target leukocyte cystine <1 nmol/mg protein). Delayed-release (Procysbi): twice daily. Ocular cystine: cysteamine eye drops (0.55%, every hour while awake). Fanconi syndrome: sodium bicarbonate, phosphate, calcitriol and potassium supplementation. ESRD: kidney transplantation (cysteamine continued after transplantation). |
| 11. Prognosis | Early cysteamine treatment (started within the first year of life) greatly extends the time to ESRD. ESRD at 10–12 years without treatment. Multisystem involvement (myopathy, lung, nervous system, endocrine) continues after transplantation, so lifelong cysteamine treatment is essential. With long-term treatment, near-normal adult functioning can be maintained. |
| 12. Prevention | Primary: genetic counseling, prenatal diagnosis (CTNS gene), PGT-M. Secondary: addition to newborn metabolic screening under discussion; early testing of infants with a family history. Tertiary: monitoring of cysteamine adherence (regular leukocyte cystine measurement), regular assessment of multisystem complications (ophthalmologic, renal, endocrine, neuromuscular, respiratory). |
| 13. References | Gahl WA et al. N Engl J Med. 2002 … and 9 other papers |
The history of cystinosis begins in 1903, when the German chemist Emil Abderhalden first reported a case of infant death with cystine crystals deposited in the liver, spleen and kidneys. At the time it was described simply as a postmortem finding, but in 1924 Gijsbertus Lignac of the Netherlands named it 'Lignac's cystinosis' and recognized the deposition of cystine crystals in the kidneys, cornea and other organs as a clinical disease.
In 1957, Verbist et al. confirmed that abnormally large amounts of cystine are present in free form in the tissues of patients with cystinosis, and in 1969 Schneider et al. demonstrated that selective excessive accumulation of cystine within lysosomes is the core of this disease. This established cystinosis as one of the first lysosomal storage diseases to be characterized. During this period, Fanconi syndrome was also confirmed as the main renal manifestation of cystinosis.
The watershed in the history of treatment came in 1976, when Tony Schneider (Jerry Schneider) first attempted cystine depletion therapy using cysteamine. Cysteamine reduces the disulfide bond of cystine within lysosomes, converting cystine into the mixed disulfide cysteine-cysteamine and exporting it from the lysosome, thereby depleting cystine accumulation. Subsequent clinical trials demonstrated that long-term treatment preserves renal function, and in 1994 the US FDA approved cysteamine bitartrate (Cystagon).
In 1995, Town et al. and Antonarakis et al. localized the CTNS gene to the short arm of chromosome 17 (17p13.2) and showed that variants of CTNS, which encodes cystinosin, cause the disease. A large 57 kb deletion was subsequently identified as a common variant in about 60% of Western European patients. In 2013, delayed-release cysteamine (Procysbi) received FDA approval, making it possible to reduce dosing from 4 times to 2 times a day and greatly improving adherence. In the 2020s, various experimental approaches, such as combination therapy with an mTOR inhibitor (everolimus) and cysteamine, stem cell correction therapy and gene editing (CRISPR), are being studied at the preclinical stage.
Cystinosis is an autosomal recessive lysosomal storage disease caused by pathogenic variants in the CTNS gene located on the short arm of chromosome 17 (17p13.2). The CTNS gene consists of 12 exons and encodes cystinosin, a lysosomal membrane transport protein of 367 amino acids.
Cystinosin is a lysosomal membrane transporter with 7 transmembrane domains that functions as an H⁺/cystine cotransporter, exporting cystine from the lysosome to the cytoplasm. When cystinosin is deficient because of CTNS variants, cystine in the lysosome cannot be exported and accumulates in crystal form. Cystine crystals damage the lysosome and adjacent cell organelles and induce apoptosis and mitochondrial dysfunction.
The most common variant is a large deletion of about 57 kb including exons 1–10 of the CTNS gene, found in about 60% of Western European patients. This deletion is presumed to be due to a founder effect and is associated with severe (infantile) cystinosis. In Asian patients, including Koreans, this deletion is rare and point mutations (missense, nonsense) are reported more frequently. Phenotypic severity is classified according to residual cystinosin function into the infantile form (severe, loss of CTNS function), the juvenile/intermediate form (partially preserved CTNS function) and the adult ocular form (relatively preserved CTNS function).
Cystinosis follows an autosomal recessive mode of inheritance. The CTNS gene is located on the short arm of chromosome 17 (17p13.2), is about 23 kb in size and consists of 12 exons. Patients are homozygous or compound heterozygous, with pathogenic variants on both alleles of the CTNS gene.
Heterozygous carriers are generally clinically asymptomatic and have leukocyte cystine levels intermediate between normal individuals and affected patients. The recurrence risk for carriers is 25% for siblings. When a variant has been identified in the family, genetic testing is recommended for both heterozygous carrier parents.
The most common variant, the 57 kb deletion, is presumed to have arisen by homologous recombination between Alu repeat sequences upstream of the CTNS gene. This deletion can be confirmed with a single test (MLPA or quantitative PCR). In Western European patients, the carrier frequency of this deletion is about 1/180. Small variants such as point mutations are detected by NGS-based single-gene CTNS analysis. In genotype–phenotype correlations, loss-of-function variants including the 57 kb deletion are associated with the infantile (severe) form, and missense variants (preserving residual function) with the juvenile or adult ocular form.
Cystinosis is a rare autosomal recessive disease with an incidence of about 1 in 100,000–200,000 births worldwide. It newly occurs in about 100–200 newborns per year, and there are currently estimated to be about 2,000 living patients worldwide. Nephropathic (infantile) cystinosis accounts for about 95% of the total, the juvenile/intermediate form about 5%, and the adult ocular form is very rare.
By region, relatively high incidence is reported in Western Europe, especially France, the Netherlands and Germany, because of the high frequency of the 57 kb founder deletion. The incidence is low in Asian countries, including Korea, but cases are steadily reported. Experience in diagnosing cystinosis has accumulated at major children's hospitals in Korea, such as Asan Medical Center, and patients are managed through the rare disease Special Copayment Reduction (V117) system.
The sex ratio of nephropathic cystinosis is nearly equal, and symptoms of Fanconi syndrome (polyuria, growth failure, rickets) first appear at about 6–12 months after birth. In the era before cysteamine treatment, end-stage renal failure was reached at 10–12 years, but early cysteamine treatment can extend preservation of renal function into the 20s–30s and beyond. Because cystinosis is not included in Korean newborn screening, diagnosis is sometimes delayed until the first symptoms (growth failure, rickets, polyuria) appear.
The core pathophysiology of cystinosis is cell damage due to progressive accumulation of cystine crystals in lysosomes. Normally, when intracellular proteins are degraded in lysosomes, amino acids including cystine cross the lysosomal membrane through the cystinosin transporter and are exported to the cytoplasm. When cystinosin is deficient, cystine accumulates in crystal form within the lysosome.
Mechanism of cell damage: cystine crystals in the lysosome mechanically damage the lysosomal membrane and increase its permeability, so acid hydrolases leak into the cytoplasm. In addition, cystine itself is directly toxic to mitochondria, reducing ATP production. ATP deficiency impairs Na⁺/K⁺-ATPase activity, which leads to loss of function of Na⁺-dependent cotransporters overall (SGLT2, NaPi-IIa, B⁰AT1, etc.), producing proximal tubular Fanconi syndrome.
Mechanism of multisystem involvement: cystine crystals accumulate not only in the renal proximal tubules but in all dividing cells, including corneal epithelial cells (photosensitivity → mucosal keratitis), thyroid follicular cells (pseudohypothyroidism), pancreatic β cells (insulin-dependent diabetes), skeletal muscle (distal myopathy, dysphagia), the central and peripheral nervous systems, retina and gonads. After kidney transplantation, blood cystine levels decrease partly with functional recovery of the transplanted kidney, but cystine accumulation in extrarenal tissues is not corrected by transplantation, so continued cysteamine treatment is essential.
The clinical symptoms of cystinosis differ greatly by phenotype (infantile, juvenile/intermediate, adult ocular), with the infantile form being the most severe.
Symptoms of the infantile (nephropathic) form: symptoms of Fanconi syndrome begin at 6–12 months of age. Polyuria and polydipsia are the first symptoms, first noticed by parents as excessive wetting of diapers. Growth failure and rickets (hypophosphatemic) are prominent, and genu valgum and growth delay become clear after age 1. Loss of appetite, nausea and vomiting, and lethargy due to metabolic acidosis recur. Photophobia due to deposition of corneal cystine crystals begins to appear at 6–18 months of age. Without treatment, end-stage renal failure is reached at 10–12 years.
Symptoms of the juvenile/intermediate form: declining renal function first appears at 10–25 years, with Fanconi syndrome later and milder than in the nephropathic form. Corneal cystine crystals are also present, but photophobia is relatively mild.
Symptoms of the adult ocular form: only corneal cystine crystals and photophobia, without renal or systemic involvement.
Progressive multisystem symptoms (with insufficient treatment): if cysteamine treatment is not continued after kidney transplantation, distal myopathy (dysphagia, respiratory muscle weakness, limb weakness), pancreatic endocrine insufficiency (diabetes), hypothyroidism, central nervous system involvement (cognitive decline, leukoencephalopathy) and male infertility progress.
The physical signs of cystinosis are most prominent in the infantile form and vary with age and treatment status.
Ophthalmologic signs: on slit lamp examination, corneal cystine crystals are seen from infancy (6–18 months) onward as numerous small crystals arranged radially. This finding is so specific for cystinosis that the ophthalmologic findings alone strongly suggest the diagnosis. Photophobia (glare, excessive tearing) accompanies it. Retinal pigment changes may appear in the juvenile or adult form.
Growth and musculoskeletal signs: severe growth failure (height and weight markedly below age expectations). Findings of rickets on X-ray (irregular epiphyses, bowing of long bones, Looser zones). Muscle weakness (impaired finger flexion and extension and dysphagia in advanced myopathy).
Renal and metabolic signs: urine dipstick positive for glucose (with normal blood glucose) and protein. Quantitative urine testing shows generalized aminoaciduria and markedly elevated β2-microglobulin. Serum hypophosphatemia, hypokalemia, metabolic acidosis. With CKD progression, elevated BUN and creatinine, anemia, hypertension.
Signs in other systems: enlargement or fibrotic changes on thyroid palpation (with insufficient treatment). Elevated blood glucose (with pancreatic β-cell damage). On electron microscopy, lysosomal cystine crystals in tissue are seen with a characteristic hexagonal or rectangular shape.
Screening for cystinosis consists of targeted screening based on family history and testing based on clinical suspicion. Cystinosis is currently not included in Korean newborn screening (NBS).
Family history-based screening: when a sibling or parent has cystinosis or is a confirmed CTNS carrier, early leukocyte free cystine measurement and urinalysis are performed in the newborn or infant. In particular, when a familial variant such as the 57 kb deletion has been identified, prenatal diagnosis or preimplantation genetic testing (PGT-M) is offered.
Screening based on clinical suspicion: if an infant has the following findings, cystinosis is immediately suspected and screening tests are performed: ① growth failure of unknown cause, ② hypophosphatemic rickets, ③ glucosuria + aminoaciduria (with normal blood glucose), ④ corneal photosensitivity. Simultaneous detection of glucosuria and aminoaciduria suggests Fanconi syndrome, and because cystinosis is its most common cause in children, confirmatory testing proceeds directly.
Confirmatory tests: quantification of free cystine in leukocytes (including polymorphonuclear leukocytes) (LC-MS/MS method): normal <0.2 nmol cystine/mg protein, heterozygous carriers 0.2–0.5, affected patients ≥0.5–2.0. It must be measured before cysteamine treatment. Slit lamp examination (corneal cystine crystals): high sensitivity at 6 months of age or older.
Cystinosis is confirmed by two methods: quantification of leukocyte free cystine and CTNS gene analysis.
Leukocyte free cystine quantification (confirmatory test): oxidized cystine is quantified in leukocytes or polymorphonuclear leukocytes (LC-MS/MS method). Normal <0.2 nmol cystine/mg protein, heterozygous carriers 0.2–0.5, affected patients ≥0.5 nmol cystine/mg protein (generally 0.5–2.5). In patients on cysteamine treatment, this test is also used to monitor treatment response, and the treatment target is <1.0 nmol cystine/mg protein.
CTNS gene analysis: NGS-based single-gene testing detects point mutations, small deletions/insertions and splicing variants. The 57 kb deletion common in Western European patients is confirmed by MLPA (Multiplex Ligation-dependent Probe Amplification) or quantitative PCR. However, some variants are deep intronic or regulatory region variants that may not be detected by standard NGS, so leukocyte cystine measurement remains an essential confirmatory test.
Supplementary tests: ophthalmologic slit lamp (corneal cystine crystals), urine amino acid quantification (generalized aminoaciduria), phosphate TRP (<85%), urine β2-microglobulin, serum electrolytes and blood gases, renal function (creatinine, GFR). Kidney biopsy helps confirm the diagnosis through characteristic hexagonal/rectangular cystine crystals on electron microscopy but is generally unnecessary in clinical practice.
Treatment of cystinosis rests on three pillars: early initiation, long-term maintenance and management of multisystem complications.
Cysteamine treatment: cysteamine reduces the disulfide bond of cystine within lysosomes to form the mixed disulfide cysteine-cysteamine, which is exported from the lysosome through the lysine transporter (PQLC2), depleting cystine. Oral cysteamine bitartrate (Cystagon): 50–90 mg/kg/day in 4 divided doses. Delayed-release cysteamine (Procysbi): 1.3–1.95 g/m²/day, in 2 doses 12 hours apart. Treatment target: leukocyte cystine <1.0 nmol/mg protein 6 hours after a dose. Gastrointestinal adverse effects (nausea, vomiting, odor) are reduced by taking it with food. It is started immediately at diagnosis and continued lifelong.
Treatment of ocular cystine: cysteamine eye drops (0.55%) are given every hour while awake to dissolve corneal cystine crystals. Corneal transplantation (if needed, for severe corneal damage).
Correction of Fanconi syndrome: sodium bicarbonate (NaHCO₃) or a potassium–sodium citrate mixture (target HCO₃⁻ >18 mEq/L), oral sodium and potassium phosphate supplementation (25–60 mg/kg/day), calcitriol (0.25–0.5 μg/day), potassium supplementation and adequate fluid intake.
Management after loss of renal function: kidney transplantation is the standard treatment for ESRD, and cysteamine treatment must be continued after transplantation to suppress multisystem (muscle, nervous system, endocrine, ocular) progression. Growth hormone (rGH): considered in children with growth failure while renal function is preserved. Additional treatment for each multisystem symptom (thyroid hormone replacement, insulin therapy, gastrostomy for dysphagia, etc.).
The prognosis of cystinosis varies greatly depending on when cysteamine treatment is started and long-term adherence.
Renal prognosis: in the era before cysteamine treatment, nearly 100% of patients with the infantile form reached ESRD at 10–12 years. Among patients who started cysteamine treatment within the first year of life, the proportion preserving renal function until 25–30 years has increased. A long-term follow-up cohort published in 2025 reported that the dialysis rate at age 30 in the early treatment group was reduced by more than 40% compared with the untreated group. After kidney transplantation, function of the transplanted kidney is generally well maintained.
Multisystem prognosis: If cysteamine therapy is not continued after kidney transplantation, distal myopathy (swallowing difficulty, respiratory muscle weakness), pancreatic diabetes, hypothyroidism, and central nervous system involvement progress in the 30s–40s. Continued cysteamine therapy can markedly delay the onset and progression of these complications.
Quality of life and life expectancy: In patients receiving early and continuous treatment, preservation of function into adulthood and social participation are possible. Poor treatment adherence (mainly due to gastrointestinal adverse effects and odor) is the main barrier to long-term prognosis. Adherence is improving with the introduction of extended-release formulations.
Prevention of cystinosis consists of genetic counseling and preimplantation/prenatal diagnosis, together with early diagnosis and prevention of complications.
Primary prevention: Through genetic counseling for families of patients with cystinosis, carrier testing (CTNS gene analysis) and an explanation of the recurrence risk (25%) are provided. Preimplantation genetic testing (PGT-M) or prenatal diagnosis (CTNS gene analysis after CVS/amniocentesis) is presented as an option. Adding cystinosis to newborn screening is under discussion in some countries.
Secondary prevention: In infants with a family history, confirmation before diagnosis is attempted with early (3–6 months) leukocyte cystine measurement and ophthalmologic examination. When clinical symptoms (polyuria, growth failure, rickets) appear, cystinosis is suspected immediately and confirmatory testing is performed so that cysteamine therapy can be started as early as possible. Eye-drop treatment (cysteamine eye drops) for corneal cystine crystals is started early.
Tertiary prevention: Leukocyte cystine levels are measured at 3–6-month intervals to monitor adherence to cysteamine therapy. Regular follow-up of the kidneys, eyes, endocrine, neuromuscular, and respiratory systems is performed to detect progression of multisystem complications early. In particular, thorough patient and caregiver education is provided so that cysteamine therapy is continued without interruption after kidney transplantation.
Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347(2):111–121. DOI: 10.1056/NEJMra020552 PMID: 12110740.
Elmonem MA, Veys KR, Soliman NA, et al. Cystinosis: a review. Orphanet J Rare Dis. 2016;11(1):47. DOI: 10.1186/s13023-016-0426-y PMID: 27102039.
Nesterova G, Gahl WA. Cystinosis: the evolution of a treatable disease. Pediatr Nephrol. 2013;28(1):51–59. DOI: 10.1007/s00467-012-2242-5 PMID: 22810155.
Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother. 2004;5(11):2255–2262. DOI: 10.1517/14656566.5.11.2255 PMID: 15500372.
Greco M, Brugnara M, Zaffanello M, et al. Long-term outcome of nephropathic cystinosis: a 20-year single-center experience. Pediatr Nephrol. 2010;25(12):2459–2467. DOI: 10.1007/s00467-010-1598-3 PMID: 20680322.
Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med. 2007;147(4):242–250. DOI: 10.7326/0003-4819-147-4-200708210-00006 PMID: 17709758.
Town M, Jean G, Cherqui S, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet. 1998;18(4):319–324. DOI: 10.1038/ng0498-319 PMID: 9537412.
Ariceta G, Ballarín J, Caramelo C, et al. Cystinosis: clinical, biochemical and genetic aspects. Nefrologia. 2015;35(3):232–242. DOI: 10.1016/j.nefro.2015.04.003 PMID: 26208508.
Ivanova EA, Elmonem MA, Van den Berghe G, et al. Altered mTOR signaling and autophagy in cystinosin-deficient human proximal tubular cells. Pediatr Res. 2016;79(3):420–428. DOI: 10.1038/pr.2015.231 PMID: 26587672.
Dello Strologo L, Pras E, Pontesilli C, et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol. 2002;13(10):2547–2553. DOI: 10.1097/01.asn.0000029586.17680.e5 PMID: 12239248.